Evidence map›Paper›PMID 35357776›Full record

ArticleChemMedChem2022

Design and Synthesis of Oligopeptidic Parvulin Inhibitors.

Nicola Relitti, A Prasanth Saraswati, Gabriele Carullo, Alessandro Papa, Alessandra Monti, Rosaria Benedetti, Eugenia Passaro, Simone Brogi, Vincenzo Calderone, Stefania Butini and 4 more

Open access · hybridAbstract read
In one paragraph

Article in ChemMedChem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Nicola RelittiDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0001-9783-8966
A Prasanth SaraswatiDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0002-9809-8936
Gabriele CarulloDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0002-1619-3295
Alessandro PapaDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0001-8141-3648
Alessandra MontiInstitute of Biostructures and Bioimaging, National Research Council, 80131, Naples, Italy.ORCID 0000-0002-6789-7057
Rosaria BenedettiDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.ORCID 0000-0001-5517-5519
Eugenia PassaroDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.ORCID 0000-0002-8018-3737
Simone BrogiDepartment of Pharmacy, University of Pisa, 56126, Pisa, Italy.ORCID 0000-0001-9375-6242
Vincenzo CalderoneDepartment of Pharmacy, University of Pisa, 56126, Pisa, Italy.ORCID 0000-0002-1441-5421
Stefania ButiniDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0002-8471-0880
Sandra GemmaDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0002-8313-2417
Lucia AltucciDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.ORCID 0000-0002-7312-5387
Giuseppe CampianiDepartment of Biotechnology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.ORCID 0000-0001-5295-9529
Nunzianna DotiInstitute of Biostructures and Bioimaging, National Research Council, 80131, Naples, Italy.ORCID 0000-0003-2952-6658
University of Siena · ITUniversity of Campania "Luigi Vanvitelli" · ITInstitute of Biostructure and Bioimaging · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pin1 catalyzes the cis-trans isomerization of pThr-Pro or pSer-Pro amide bonds of various proteins involved in several physio/pathological processes. In this framework, recent research activity is directed toward the identification of new selective Pin1 inhibitors. Here, we developed a set of peptide-based Pin1 inhibitors. Direct-binding experiments allowed the identification of the peptide-based inhibitor 5 k (methylacetyl-l-alanyl-l-histidyl-l-prolyl-l-phenylalaninate) as a potent ligand of Pin1. Notably, 5 k binds Pin1 with higher affinity than Pin4. The comparative analysis of molecular models of Pin1 and Pin4 with the selected compound gave a rational explanation of the biochemical activity and pinpointed the chemical elements that, if opportunely modified, may further improve inhibitory potency, pharmacological properties, and selectivity of future peptide-based parvulin inhibitors. Since 5 k showed limited cell penetration and no antiproliferative activity, it was conjugated to a polyarginine stretch (R8), known to promote cell penetration of peptides, to obtain the R8-5 k derivative, which displayed antiproliferative effects on cancer cell lines over non-tumor cells. The effect of R8 on cell proliferation was also investigated. This work warrants caution about applying the R8 strategy in the development of cell-penetrating antiproliferative peptides, as it is not inert.

Indexed as

PeptidesPeptidylprolyl IsomeraseModels, MolecularNIMA-Interacting Peptidylprolyl IsomerasePhosphorylationNIMA-Interacting Peptidylprolyl IsomerasePeptidesPeptidylprolyl Isomerasebiological activitymolecular modellingpeptide synthesisPin1/4PPIase

Identifiers

PMID35357776
PMCPMC9321596
OpenAlexW4221125546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.